Affitech AS and Peregrine Pharmaceuticals Announce Research Milestone Achievement by Affitech

Peregrine Pharmaceuticals Announces Patent Grant for Vasopermeation Enhancement Technology

Peregrine Pharmaceuticals to Present at the UBS Global Specialty Pharmaceuticals Conference

Review of Peregrine's Anti-VEGF Technology Presented at Third Annual Angiogenesis Conference

Review of Peregrine's Anti-Phospholipid Therapy Program Presented at Second International Conference on Vascular Targeting

Peregrine's Vascular Targeting Agent Technology Presented at Second International Conference on Vascular Targeting

Peregrine Pharmaceuticals Provides Company Update

Peregrine Pharmaceuticals Finalizes Agreement to Evaluate VTA Platform for Treatment of Ocular Disease

Peregrine's VTA Inhibits Growth of Breast Cancer Tumor Metastases by up to 58 Percent

Peregrine's Anti-Angiogenesis Agent Inhibits Growth of Blood Vessels by up to 85% in Breast Cancer Tumor Metastases